<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00875355</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000633496</org_study_id>
    <secondary_id>CLCC-IC-RT-TEMODAL</secondary_id>
    <secondary_id>CLCC-IC-2007-01</secondary_id>
    <secondary_id>INCA-RECF0630</secondary_id>
    <secondary_id>EUDRACT-2007-002531-83</secondary_id>
    <secondary_id>SCHER-CLCC-IC-RT-TEMODAL</secondary_id>
    <nct_id>NCT00875355</nct_id>
  </id_info>
  <brief_title>Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast Cancer</brief_title>
  <official_title>Phase II Randomized Multicenter Study Comparing Brain Radiation in Combination With Temozolomide or Radiation Alone in Patients With Brain Metastases From Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in&#xD;
      chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells,&#xD;
      either by killing the cells or by stopping them from dividing. It is not yet known whether&#xD;
      radiation therapy is more effective when given alone or together with temozolomide in&#xD;
      treating brain metastases secondary to breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well radiation therapy given together&#xD;
      with temozolomide works compared with radiation therapy given alone in treating women with&#xD;
      brain metastases and breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the objective response rate at 6 weeks in women with brain metastases secondary&#xD;
           to breast cancer treated with radiotherapy with vs without temozolomide.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate the tolerability.&#xD;
&#xD;
        -  Compare the duration of response.&#xD;
&#xD;
        -  Compare local progression-free survival.&#xD;
&#xD;
        -  Compare overall survival.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients undergo isocentric radiotherapy to the brain 5 times a week for 2 weeks.&#xD;
&#xD;
        -  Arm II: Patients undergo radiotherapy as in arm I and receive oral temozolomide once&#xD;
           daily for 2 weeks.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 3 and 6 months and then every 6&#xD;
      months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <primary_completion_date type="Anticipated">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Response at 6 weeks as assessed by MRI and/or scan</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo isocentric radiotherapy to the brain 5 times a week for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo radiotherapy as in arm I and receive oral temozolomide once daily for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Patients undergo radiotherapy</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of breast cancer&#xD;
&#xD;
               -  Unresectable disease or patient refused surgery&#xD;
&#xD;
          -  Must have brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Liver transaminases ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No carcinomatous meningitis&#xD;
&#xD;
          -  No history of cancer except for basal cell carcinoma of the skin or carcinoma in situ&#xD;
             of the cervix&#xD;
&#xD;
          -  No other serious concurrent disease that is, in the opinion of the investigator,&#xD;
             likely to interfere with study evaluation and treatment&#xD;
&#xD;
          -  No contraindications to treatment with temozolomide&#xD;
&#xD;
          -  No psychological, familial, social, or geographic situations that preclude clinical&#xD;
             follow up&#xD;
&#xD;
          -  No patient deprived of liberty or under guardianship&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior brain radiotherapy&#xD;
&#xD;
          -  At least 10 days since prior chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Youlia Kirova</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Curie Hopital</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youlia Kirova</last_name>
      <phone>33-44-32-4000</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>April 2, 2009</study_first_submitted>
  <study_first_submitted_qc>April 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2009</study_first_posted>
  <last_update_submitted>August 25, 2009</last_update_submitted>
  <last_update_submitted_qc>August 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2009</last_update_posted>
  <keyword>tumors metastatic to brain</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

